European Psychiatry - Volume 33 - March 2016

297 / 812

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348 S293
schizophrenia. Abs hydrolyzing DNA were detected in pool of poly-
clonal autoantibodies in autoimmune and infectious diseases, such
catalytic Abs were named abzymes.
Objectives To investigate the level of anti-DNA antibodies and
DNA-hydrolyzing activity of IgG from the serum of patients with
schizophrenia depending on leading clinical symptoms.
Aims – To measure the concentration of anti-DNA Abs in serum
of patients with leading positive and negative symptoms;
– to determine DNA-hydrolyzing activity of IgG.
Methods In our study, 51 patients were included. The levels of
antiDNAAbswere determined using ELISA. DNA-hydrolyzing activ-
ity was detected as the level(%) of supercoiled pBluescript DNA
transition in circular and linear forms. Statistical analysis was per-
formed in “Statistica 9.0”.
Results Anti-DNA Abs of patients with schizophrenia not only
bind DNA, but quite efficiently hydrolyze the substrate. IgG of
patient with schizophrenia were shown to possess DNA hydrolyz-
ing activity. It should be noted that DNAase activity of IgG in
patients with schizophrenia with a negative symptoms was signif-
icantly higher, than in patients with positive symptoms
Conclusions The data show a correlation with the level of DNase
activity and leading symptoms of patients with schizophrenia.
Table 1 Concentration of anti-DNA Abs and relative hydrolysis of
DNA in different groups of patients with schizophrenia.
Groups of patients Concentration of anti-DNA
Abs U/mL (M ±SD)
Relative
hydrolysis
of DNA(%)
Anti-ssDNA Anti-dsDNA
Healthy donors
(n = 24)
7.4 ± 2.7 6.9 ± 0.9 9,1 ±6,5
Total group of
patients with
schizophrenia
(n = 51)
6.9 ± 3.7 7.4 ± 3.7 55.4 ±32.6*
Positive
symptoms
(n = 25)
7.2 ± 4.1 5.3 ± 3.05 43.3 ±33.1
Negative
symptoms
(n = 26)
5.4 ± 2.4* 7.9 ± 4.5 73.3 ±23.8**
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW511
Clinical and functional outcomes of
patients with severe schizophrenia
undergoing comprehensive
treatment: A 6-year follow-up
J.J. Fernandez-Miranda ∗ iaz-Fernandez
SESPA, AGCSM-V, Gijon, Spain
∗ Corresponding author.
Introduction To increase treatment compliance and conse-
quently to reach clinical and rehabilitation goals in people with
schizophrenia is a main challenge in their treatment.
Objectives and aims To know the retention in treatment (and rea-
sons for discharge) of people with severe schizophrenia enrolled in
a specific, intensive, comprehensive and community programme
for them; and also to know treatment (clinical and functional) out-
comes.
Methods A 6-year prospective, observational study of patients
with severe schizophrenia (ICD 10: F 20; CGI-S ≥ 5) undergoing
specific severe mental illness programme (n = 200). Assessment
included the Clinical Global Impression-Severity scale (CGI-S), the
Camberwell Assessment of Needs (CAN) and the WHO Disability
Assessment Schedule (WHO-DAS). Time in treatment and reasons
of discharge were measured. Laboratory tests, weight and medica-
tions were reported. Hospital admissions were measured.
Results CGI at baseline was 5.86 ± 0.7. After 6 years 48% of
patients continued under treatment (CGI = 4.31 ±0.8; P < 0.01);
31% were medical discharged (CGI = 3.62± 1.6; P < 0.001); DAS
decreased in the four areas (P < 0.01) and also CAN (P < 0.01); 7% had
moved to other places; 8%were voluntary discharges. Eight patients
dead; three of them committed suicide. Forty-five percent of all of
them were treated with atypical long-acting antipsychotics, with
good tolerability. There were significantly less hospital admissions
than during the previous 6 years (P < 0.001).
Conclusions Retention of severe mentally ill patients with
schizophrenia in a specific and intensive care programme was
really high; and seemed to help getting in remarkable clinical and
functional improvement. Long-acting medication also seemed to
be useful on improving treatment adherence, mainly due to their
good tolerability.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW512
Depressive symptoms in a sample of
patients diagnosed with
schizophrenia
A. Fernandez-Quintana∗, M.D.C. García-Mahía
Clinical university hospital of La Coru˜na, psychiatry, La Coru˜na, Spain
∗ Corresponding author.
Introduction Previous studies highlight the difficulty of correctly
diagnosing depressive symptoms in schizophrenic patients, as well
as the impact on clinical progression among patients who present
with both syndromes, worsening treatment adherence and overall
prognosis.
Aims To determine the prevalence of depressive symptoms in
patients diagnosed with schizophrenia. To analyze the relation-
ship of depressive symptoms with other demographic and clinical
variables.
Material and methods Eighty-four patients diagnosed with
schizophrenia according to ICD-10 criteria and treated in an Outpa-
tient Mental Health Clinic were recruited for this study. Symptom
severity was assessed using The Positive and Negative Syndrome
Scale (PANSS; Kay et al., 1987); classifying patients as positive,
negative or mixed schizophrenia subtypes. Data from clinical and
sociodemographic variables was obtained from clinical records.
Results The mean age was 43.2 years (SD: 10.2). Depression
is objectively detected in 10.3% of the sample, and presented as
subjective depression in 29.5%. The prevalence of depressive symp-
toms is higher among women, unmarried patients, lower social
classes and patients who met criteria for predominantly positive
Schizophrenia subtype. Higher prevalence of depressive symptoms
was found in patients with a shorter course of disease.
Conclusions Depressive symptoms present with a high preva-
lence among patients diagnosed with schizophrenia, especially
during the early years of the disease. Given the severe impact of
depression on both the evolution and prognosis of patients with
severe mental illness, screening and early treatment must be car-
ried out.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.